- Home
- NVO vs ABBV Comparison
NVO vs ABBV Comparison
Compare NVO & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVO
- ABBV
- Stock Information
- Founded
- NVO 1923
- ABBV 2012
- Country
- NVO Denmark
- ABBV United States
- Employees
- NVO N/A
- ABBV N/A
- Industry
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- NVO Health Care
- ABBV Health Care
- Exchange
- NVO Nasdaq
- ABBV Nasdaq
- Market Cap
- NVO 278.0B
- ABBV 329.1B
- IPO Year
- NVO N/A
- ABBV N/A
- Fundamental
- Price
- NVO $65.73
- ABBV $184.55
- Analyst Decision
- NVO Strong Buy
- ABBV Buy
- Analyst Count
- NVO 4
- ABBV 23
- Target Price
- NVO $128.00
- ABBV $212.00
- AVG Volume (30 Days)
- NVO 11.2M
- ABBV 7.7M
- Earning Date
- NVO 05-07-2025
- ABBV 04-25-2025
- Dividend Yield
- NVO 2.45%
- ABBV 3.56%
- EPS Growth
- NVO 17.93
- ABBV N/A
- EPS
- NVO 3.40
- ABBV 2.34
- Revenue
- NVO $43,922,211,349.00
- ABBV $57,367,000,000.00
- Revenue This Year
- NVO $20.22
- ABBV $7.79
- Revenue Next Year
- NVO $16.10
- ABBV $7.92
- P/E Ratio
- NVO $19.32
- ABBV $78.88
- Revenue Growth
- NVO 24.11
- ABBV 5.45
- 52 Week Low
- NVO $57.00
- ABBV $153.58
- 52 Week High
- NVO $148.15
- ABBV $218.66
- Technical
- Relative Strength Index (RSI)
- NVO 48.22
- ABBV 45.05
- Support Level
- NVO $64.40
- ABBV $181.64
- Resistance Level
- NVO $69.67
- ABBV $198.98
- Average True Range (ATR)
- NVO 1.74
- ABBV 5.34
- MACD
- NVO 0.85
- ABBV 0.73
- Stochastic Oscillator
- NVO 62.20
- ABBV 48.59
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).